Genotyping NUDT15, TPMT and CEP72

DNA strand for Precision Medicine

Genotyping NUDT15, TPMT and CEP72

Genotyping panels

The CNT (CEP72, NUDT15, and TPMT) and NT (NUDT15 and TPMT) genotyping panels investigate all clinically relevant genetic variants in these actionable pharmacogenetics (PGx) genes in a single test. Rather than testing a limited number of variants in other platforms, our comprehensive panels yield thorough dosing guidelines for thiopurines and vincristine with higher accuracy.

TPMT and NUDT15 are two important PGx genes recommended in the latest CPIC guidelines to guide proper dosing of thiopurines, including azathioprine, mercaptopurine, and thioguanine. Thiopurines are  commonly used drugs to treat acute lymphoblastic leukemia (ALL), autoimmune diseases, and inflammatory bowel disease (IBD), or to prevent rejection after organ transplant.1 Variants in TPMT and NUDT15 are associated with increased risk of life-threatening myelosuppression induced by thiopurines.1,2,3

Whereas TPMT variants are primarily found in those of European descent, genetic variants in NUDT15 are found in many populations (Figure 1).2

CNT Pane NUDT15 Diplotype Variants

One genetic variant of CEP72 has been associated with vincristine-related peripheral neuropathy. Thus, genotyping of CEP72 is recommended to guide safer dosing of vincristine.4

Download Brochure

Order A Test

Learn how easy it is to order a test.

KEY ADVANTAGES

Covers CPIC guideline-recommended genes in one test

Analyze both CPIC guideline-recommended genes, TPMT and NUDT15, for thiopurines in a single test.

Test all clinically relevant variants

Test all clinically relevant variants of TPMT, NUDT15, and CEP72 to enhance accuracy and eliminate guesswork.

Rapid turnaround time (TAT)

Highly accurate clinical results are delivered within 3-5 days to support potentially life-saving clinical decision making.

CNT allele table

Testing for individual gene, NUDT15, is also available. Contact us for more information.

NUDT15

Download NUDT15 Spec Sheet

NUDT15 encodes an enzyme (nudix hydrolase) which is a negative regulator of thiopurines (e.g., 6-mercaptopurine, azathioprine, thioguanine, etc.) activation and toxicity. Genetic variants in the NUDT15 gene can modulate enzymatic activity and the metabolism of thiopurines.1,2,3

Pharmacogenetic testing for these variants can identify individuals who may fail to respond to standard dosages of drugs metabolized by NUDT15 or be at an increased risk of adverse drug reactions.

The latest CPIC guidelines recommend testing for NUDT15 and TPMT to guide the dosing of thiopurines. Read more.

A recent landmark study shows NUDT15 variants are associated with thiopurine-induced myelosuppression in patients with IBD. Read more.

Read more about NUDT15.

Single gene testing for NUDT15 is also available. Please contact us for more information.

TPMT

Download TPMT Spec Sheet

TPMT encodes an enzyme that is a negative regulator of thiopurines (e.g., 6-mercaptopurine, azathioprine, thioguanine, etc.) activity. Genetic variants of the TPMT gene can modify enzymatic activity and the ability to metabolize thiopurines.1 Pharmacogenetic testing for these variants can identify individuals who may have an increased risk of having adverse drug reactions or may fail to respond to standard dosages of drugs metabolized by TPMT.

Read more about TPMT.

The latest CPIC guidelines recommend testing for NUDT15 and TPMT to guide the dosing of thiopurine. Read more.

CEP72

Download CEP72 Spec Sheet

CEP72 encodes a protein that is essential for microtubule formation. The chemotherapeutic drug vincristine exerts its cytotoxic effects by interfering with microtubule formation and mitotic spindle dynamics, leading to mitotic arrest and cell death. One specific sequence variant in CEP72 (T/T genotype) is associated with an increased risk and severity of vincristine-related peripheral neuropathy in individuals ALL.4

REFERENCES
  1. Relling MV, et al. CPIC Guideline for Thiopurines and TPMT and NUDT15. Clin Pharmacol Ther. 2019 May;105(5):1095-1105.
  2. Moriyama T, et al. NUDT15 Polymorphisms Alter Thiopurine Metabolism and Hematopoietic Toxicity. Nat Genet. 2016 Apr;48(4):367-73.
  3. Schaeffeler, E. et al. Impact of NUDT15 Genetics on Severe Thiopurine-related Hematotoxicity in Patients with European Ancestry. Genetics in Medicine. Feb 2019. [Ahead of ePub].
  4. Stock W, et al. Clin Pharmacol Ther. 2017;101(3):391-95.

How to Order a Test

Learn how easy it is to order a test.